Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers

被引：0
|
作者：
Atkins, Michael [1 ]
Martini, Jean-Francois [2 ]
Plimack, Elizabeth [3 ]
McDermott, David [4 ]
Puzanov, Igor [5 ]
Fishman, Mayer [6 ]
Cho, Daniel [7 ]
Vaishampayan, Ulka [8 ]
Rosbrook, Brad [2 ]
Fernandez, Kathrine [9 ]
Tarazi, Jamal [2 ]
George, Saby [5 ]
Choueiri, Toni [10 ]
机构：
[1] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Pfizer Global Prod Dev Oncol, San Diego, CA USA
[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] NYU, Langone Med Ctr, New York, NY USA
[8] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[9] Pfizer Global Prod Dev Oncol, Cambridge, MA USA
[10] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT093
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Puzanov, Igor
    Fishman, Mayer N.
    McDermott, David F.
    Cho, Daniel C.
    Vaishampayan, Ulka N.
    George, Saby
    Olencki, Thomas
    Tarazi, Jamal Christo
    Rosbrook, Brad
    Fernandez, Kathrine C.
    Lechuga, Mariajose
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [2] Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
    Atkins, M. B.
    Plimack, E. R.
    Puzanov, I.
    Fishman, M. N.
    McDermott, D.
    Cho, D. C.
    Vaishampayan, U.
    George, S.
    Olencki, T.
    Tarazi, J.
    Rosbrook, B.
    Fernandez, K.
    Keefe, S.
    Choueiri, T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [3] Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
    Martini, Jean-Fran Comma Cois
    Plimack, Elizabeth R.
    Choueiri, Toni K.
    McDermott, David F.
    Puzanov, Igor
    Fishman, Mayer N.
    Cho, Daniel C.
    Vaishampayan, Ulka
    Rosbrook, Bradley
    Fernandez, Kathrine C.
    Tarazi, Jamal C.
    George, Saby
    Atkins, Michael B.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (21) : 5598 - 5608
  • [4] Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).
    Rini, Brian I.
    Escudier, Bernard
    Murphy, Danielle
    Wang, Panpan
    Tarazi, Jamal Christo
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, C. G.
    Eto, M.
    Motzer, R. J.
    De Giorgi, U. F. F.
    Buchler, T.
    Basappa, N. S.
    Mendez Vidal, M. J.
    Tjulandin, S.
    Park, S. H.
    Melichar, B.
    Hutson, T. E.
    Alemany, C.
    McGregor, B.
    He, C. S.
    Perini, R.
    Mody, K.
    McKenzie, J.
    Choueiri, T. K.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
  • [6] Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN plus PEMBRO) or sunitinib (SUN) in the CLEAR study.
    Voss, Martin H.
    Powles, Thomas
    McGregor, Bradley Alexander
    Porta, Camillo
    Gruenwald, Viktor
    Merchan, Jaime R.
    Rolland, Frederic
    Maroto-Rey, Pablo
    Goh, Jeffrey C.
    Xing, Dongyuan
    Perini, Rodolfo F.
    McKenzie, Jodi
    Mody, Kalgi
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma
    Spisarova, Martina
    Melichar, Bohuslav
    Vitaskova, Denisa
    Studentova, Hana
    [J]. FUTURE ONCOLOGY, 2021, 17 (03) : 241 - 254
  • [8] Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
    Spisarova, Martina
    Melichar, Bohuslav
    Vitaskova, Denisa
    Studentova, Hana
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 693 - 703
  • [9] A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC)
    McDermott, D. F.
    Infante, J. R.
    Chowdhury, S.
    Voss, M. H.
    Motzer, R. J.
    Perini, R. F.
    Morosky, A.
    Zheng, F. F.
    White, B. C.
    Wang, Q.
    Jewell, R. C.
    Rini, B. I.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S519 - S520
  • [10] Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis
    Bergamini, Marco
    Dalla Volta, Alberto
    Valcamonico, Francesca
    Caramella, Irene
    Buffoni, Martina
    Munari, Enrico
    Fisogni, Simona
    Zanotelli, Tiziano
    Suardi, Nazareno Roberto
    Berruti, Alfredo
    [J]. CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 56 - 68
12345